Ads
related to: parp inhibitors clinical trials- About PARP Inhibitors
Learn About How Treatment Works.
Learn About Maintenance Therapy.
- Safety And Side Effects
Read Important Safety Information.
Learn More About A Treatment.
- Treatment Effectiveness
Read About How Treatment Works And
Its Benefits And Risks In Patients.
- Tablet Dosing Info
Learn About Tablet Dosing For
An Ovarian Cancer Treatment.
- First-Line Maintenance
Learn About First-Line Treatment.
Download Helpful Resources & Info.
- Talk To Your Doctor
Get Resources To Help Stay Informed
To Make Your Conversation Easier.
- About PARP Inhibitors
- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
Search results
Results From The WOW.Com Content Network
Despite the clinical success of PARP inhibitors, their efficacy is limited by the development of resistance. Overcoming resistance has thus become a major focus within the PARP inhibitor research field, prompting comprehensive studies into resistance mechanisms.
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, in a process called "therapeutic repurposing". [22]
Iniparib was the first putative PARP inhibitor to commence phase III clinical trials. [8] The first was for breast cancer, [9] another was for squamous-cell lung cancer. [10] Preliminary results in June 2009 on triple-negative breast cancer were promising. [11]
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.
Pamiparib is a member of the PARP inhibitor drug class. [ 1 ] In China, it is approved for the treatment of germline BRCA mutation -associated recurrent advanced ovarian , fallopian tube , and primary peritoneal cancers previously treated with two or more lines of chemotherapy.
A 2012 study in a cell line found that PARP inhibitors exhibit cytotoxic effects not based solely on their enzymatic inhibition of PARP, but by their trapping of PARP on damaged DNA, and the strength of this trapping activity was ordered niraparib >> olaparib >> veliparib. [13]
Ads
related to: parp inhibitors clinical trials- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
